TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02332616
Drug: Isotonic Sodium Chloride
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT01643668
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
Study: NCT01643668
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
Study: NCT00262782
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
Study: NCT02179008
Drug: DE-117 Low Dose ophthalmic solution
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low Dose DE-117 ophthalmic solution
Study: NCT02179008
Drug: DE-117 Middle Dose ophthalmic solution
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Middle Dose DE-117
Study: NCT02179008
Drug: DE-117 High Dose ophthalmic solution
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High Dose DE-117
Study: NCT02179008
Drug: latanoprost ophthalmic solution 0.005%
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.005% latanoprost
Study: NCT03298802
Drug: Hydrochlorothiazide 50mg Tablet
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
Study: NCT02617771
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
Study: NCT02868801
Drug: Pregabalin SR tablet 330mg/day
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: According to the efficacy and safety in titration
Study: NCT02868801
Drug: Pregabalin SR tablet 660mg/day
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: According to the efficacy and safety in titration.
Study: NCT02477800
Drug: Aducanumab (BIIB037)
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose
Study: NCT02477800
Drug: Aducanumab (BIIB037)
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose
Study: NCT00767494
Drug: Travoprost/Brinzolamide fixed combination
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eye Drops, suspension once daily
Study: NCT00767494
Drug: Azopt
Normalized name: Azopt
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eye Drop Suspension, 1 drop BID
Study: NCT00767494
Drug: Travatan
Normalized name: Travatan
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eye Drop Solution, 1 drop BID
Study: NCT01586286
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Study: NCT01836549
Drug: imetelstat sodium
Normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01182636
Drug: Adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% Topical Gel
Study: NCT03202667
Drug: Empagliflozin 25mg
Normalized name: EMPAGLIFLOZIN 25MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with empagliflozin 25mg once daily for 28 days
Study: NCT00952133
Drug: Palonosetron only
Normalized name: Palonosetron only product
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
Study: NCT00952133
Drug: Palonosetron with Dexamethasone
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
Study: NCT03630796
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
Study: NCT03630796
Drug: TIVA
Normalized name: Ultiva
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia
Study: NCT00161200
Drug: Ranitidine & Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01969565
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01969565
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01814839
Drug: ALN-TTRSC (revusiran)
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
Study: NCT01814839
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator
Study: NCT00002814
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01738594
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01738594
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002814
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006786
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01808911
Drug: Steroid + rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04212611
Drug: INFRA ORBITAL BLOCK
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
Study: NCT01027065
Drug: CYT107+GenHevac+entecavir or tenofovir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
Study: NCT01027065
Drug: CYT107+ entecavir or tenofovir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
Study: NCT00448734
Drug: Picoplatin
Normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.
Study: NCT00448734
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.
Study: NCT00774904
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin II Type 1 Receptor Blockers
Study: NCT00804648
Drug: Timolol Maleate in Sorbate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5%
Study: NCT00804648
Drug: Timolol hemihydrate
Normalized name: Timolol Hemihydrate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5%
Study: NCT00804648
Drug: Timolol maleate gel forming solution
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5%
Study: NCT01422603
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
Study: NCT01422603
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
Study: NCT03253679
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00002893
Drug: raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939899
Drug: IXAZOMIB
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Study: NCT01761201
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin
Study: NCT01761201
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months.
Study: NCT02262767
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Pfizer compound.
Study: NCT02262767
Drug: Trimethobenzamide Hydrochloride
Normalized name: Trimethobenzamide Hydrochloride
DrugBank: Trimethobenzamide (DB00662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Study: NCT05674669
Drug: Lysergic Acid Diethylamide (LSD) 50µg
Normalized name: diethylamine salicylate / flufenamic acid / myrtecaine
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05674669
Drug: Lysergic Acid Diethylamide (LSD) 75µg
Normalized name: diethylamine salicylate / flufenamic acid / myrtecaine
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05674669
Drug: Lysergic Acid Diethylamide (LSD) 100µg
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05674669
Drug: Placebo/Lysergic Acid Diethylamide (LSD) 75µg
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05674669
Drug: Lysergic Acid Diethylamide (LSD) 50µg/75µg
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00931710
Drug: valsartan, amlodipine, HCTZ
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
Study: NCT00931710
Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
Study: NCT00579527
Drug: Rabbit anti-thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
Study: NCT00579527
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol.
Study: NCT00579527
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
Study: NCT00579527
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
Study: NCT04445935
Drug: Bivalirudin Injection
Normalized name: bivalirudin Injection
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive iv Bivalirudin according to the institutional HIT protocol.
Study: NCT04613700
Drug: Secretin
Normalized name: Secretin
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Native hormone
Study: NCT00167115
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00007163
Drug: J695
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00579527
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
Study: NCT00774397
Drug: BI 201335 NA 240 mg QD
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
Study: NCT00774397
Drug: BI 201335 NA 240 mg BID
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
Study: NCT00439413
Drug: Selegiline Transdermal Patch
Normalized name: selegiline Transdermal System
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selegiline cm(2) via transdermal system
Study: NCT03614273
Drug: Adrenaline
Normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Study: NCT05397262
Drug: Chemotherapy Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2; d1-5, 29-33
Study: NCT03466242
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
Study: NCT03466242
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate sedative and analgesic effects of Intravenous Ketamine
Study: NCT00133250
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
Study: NCT01762475
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315835
Drug: Buprenorphine transdermal delivery system
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00381706
Drug: IC
Normalized name: AIC
DrugBank: Aminoimidazole carboxamide (DB06143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin and irinotecan given IV
Study: NCT02113891
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant).
Study: NCT02804386
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
Study: NCT03069859
Drug: Placebo (0.9% saline)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study: NCT00792636
Drug: sumatriptan tablet
Normalized name: Sumatriptan Tablets
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sumatriptan 85mg
Study: NCT02147431
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp
Study: NCT00816894
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
Study: NCT00256204
Drug: Rasagiline Mesylate
Normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, 1mg once daily
Study: NCT00256204
Drug: Rasagiline Mesylate
Normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, 2mg once daily
Study: NCT04460807
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane in addition to standard therapy, in Experimental arm.
Study: NCT04425863
Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
Study: NCT03459794
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mcg/kg ivermectin, by mouth.
Study: NCT02364999
Drug: Bevacizumab-Pfizer
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
Study: NCT02364999
Drug: Bevacizumab-EU
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
Study: NCT02364999
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.